Navigation Links
Astellas and Gift of Hope Organ & Tissue Donor Network Join Forces to Raise Awareness of Need for More Organ Donors in Chicago
Date:4/19/2013

NORTHBROOK, Ill., April 19, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), and Gift of Hope Organ & Tissue Donor Network, a not-for-profit organ procurement organization that coordinates organ and tissue donation and provides public education on donation in Illinois and northwest Indiana, have collaborated to raise awareness of the need for more organ donors in the city of Chicago. As part of the efforts, Mayor Rahm Emanuel signed a proclamation declaring today, April 19, Organ Donation Awareness Day in the city of Chicago. Astellas and Gift of Hope are encouraging the Chicago community to learn more about organ donation, and register their decision to donate.

"We're proud to partner with Astellas in building a community of support around organ donation awareness and the need for more donors," said David Bosch , Director of Communications and Legislative Affairs at Gift of Hope. "The decision to be an organ donor gives hope to many people awaiting a second chance."

While organ transplantation is a remarkable story in the history of medicine, the need for organs is vastly greater than the number available for transplantation. Currently there are more than 117,000 people in the U.S. awaiting an organ transplant – including more than 5,000 people in Illinois. Each year, more than 28,000 Americans receive a donated organ, but sadly, more than 6,500 people die each year waiting for an organ.

Today's proclamation underscores Astellas' ongoing commitment to the Chicago community, as well as the national tran
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
2. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
3. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
4. Astellas to Drive PGA TOURs New Womens Initiative
5. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
7. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
8. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
9. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
10. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
11. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the Piper ... 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... New York . A live audio webcast ... section of Arena,s website at www.arenapharm.com . A replay ...
(Date:11/24/2014)... 24, 2014 Luoxis Diagnostics, Inc., a ... today announced the presentation of three clinical and ... a broadly applicable and robust research tool capable ... in response to injury, illness, or stress.  In ... with Luoxis, academic and pharmaceutical research partners, RedoxSYS ...
(Date:11/24/2014)... The Female Health Company (NASDAQ-CM: FHCO), today ... to discuss its operating results for the fourth quarter ... December 2, 2014 at 11:00 a.m. Eastern Standard Time ... earlier the same day. Shareholders and other ... dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2
... SAN FRANCISCO, Calif., May 16, 2011 diaDexus, Inc. (OTC ... on the development and commercialization of patent-protected in vitro ... announced financial results for the first quarter of 2011. ... were $3.3 million, representing 25% growth over total revenues of ...
... Oncology molecules in development will be presented during the 47th ... held in Chicago, Ill. from June 3 – 7, 2011. ... industry, with more than 30 molecules in development to treat ... these pipeline molecules are being evaluated for certain biomarkers or ...
Cached Medicine Technology:diaDexus, Inc. Reports 2011 First Quarter Financial Results 2diaDexus, Inc. Reports 2011 First Quarter Financial Results 3diaDexus, Inc. Reports 2011 First Quarter Financial Results 4diaDexus, Inc. Reports 2011 First Quarter Financial Results 5Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011 2Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011 3
(Date:11/24/2014)... SafeHandles™ announced that they will be ... Begley Jr, airing via Discovery Channel. Dates and show ... passive, non-invasive, replaceable, and affordable germ protective device. This ... sleeves and adhesives to promote hand hygiene in high ... of SafeHandles is the desire to make a positive ...
(Date:11/24/2014)... 24, 2014 "My friend was killed ... to cross the street in his motorized wheelchair," said ... him. I came up with this idea so that ... , He developed the Safety Lites to make a ... conditions. The device ensures that motorists can see the ...
(Date:11/23/2014)... November 23, 2014 The report, ... 2006 to 2020 - Asia-Pacific” provides quantitative analysis ... market segments: minimally invasive body contouring devices, non-invasive ... analysis includes market size data by revenue and ... following countries: China, Japan, South Korea, Australia and ...
(Date:11/23/2014)... friends have more influence on teens, alcohol use than ... "We,ve known for a long time that ... use, but there are no common studies that distinguished ... influence on those decisions," Jonathon Beckmeyer, an assistant professor ... a university news release. Beckmeyer analyzed data gathered ...
(Date:11/23/2014)... show thanks to new and old customers, iFitDress.com has ... for weddings. Customers who need custom outfits can talk ... dress manufacturer, and it is among the ones which have ... long time. The CEO of this company says, "iFitDress.com is ... buy not only a beautiful dress, but also a piece ...
Breaking Medicine News(10 mins):Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Close Friends May Be Key to Teens' Drinking 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... Demonstrates a 20-Meter Improvement in Six-Minute Walk ... Distance ... Time on November 1, 2007, SILVER SPRING, Md., Nov. 1 ... Rx, Inc., announced today the completion of their TRIUMPH-1 Phase 3,trial ...
... Calif., and WHITEHOUSE STATION, N.J., Nov. 1, Dynavax ... Co., Inc. (NYSE: MRK ) today announced ... develop HEPLISAV(TM), a,novel investigational hepatitis B vaccine, which ... clinical trial involving adults and in,patients on dialysis. ...
... 1 The makers of the WaveSense line ... Claudio,Carboni, formerly of Menarini Diagnostics, has joined as ... WaveSense Europe will,distribute the company,s high accuracy, WaveSense ... market both directly and through local,partners. Carboni ...
... Upload Video Confessions/ Testimonials for ... PHILADELPHIA and LONDON, Nov. 1 Thomson,Scientific, ... ; TSX: TOC) and,leading provider of information solutions ... the launch of its new campaign,"Confessions ... of ...
... (MHS), a not-for-profit health care system with hospitals ... it has selected,Integrated Healthcare Holdings, Inc. (IHHI) to ... partially physician-owned publicly traded hospital management,company, owns and ... total of,770 beds, 2787 employees and 1725 active ...
... Oct. 31 Always Best Care Senior,Services has expanded ... Living Placement Service, and Personal Response Company, is,proud to ... Always Best Care,Senior Services for outstanding care. For over ... our work - a sincere concern for,the betterment of ...
Cached Medicine News:Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 2Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 3Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 4Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 5Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 6Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 2Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 3Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 4Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 5Health News:Ex-Head of Menarini Diabetes Unit Launches WaveSense Europe 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:Memorial Health Services Announces Sale of Anaheim Memorial Medical Center 2Health News:Announcing Always Best Care Senior Services Expansion Into San Diego, California 2
... smallest handheld oximeters available, Datex-Ohmeda s TuffSat ... home care, transport, and EMS. TuffSat comes ... (relative perfusion index measurement) a quick, ... reflection of perfusion at the sensor site. ...
... the power of clinical information. , ... of clinical connectivity solutions that help you ... high-quality patient care. You will have access ... to share it with your care team ...
... For safe and easy patient monitoring during MRI, ... the special needs of the MRI environment. It ... during MRI, promoting safety and flexibility., ,Though ... offers all the key benefits of the S/5 ...
... Compact and comprehensive solution for ... Arrhythmia Workstation (ARRWS) provides one compact, ... telemetry monitored patients. It connects to ... analysis for up to 16 beds., ...
Medicine Products: